title: [Interferon therapy in Hodgkin's disease].
abstract: Though there are only limited reports interferon (IFN) seems an interesting substance for patients with Morbus Hodgkin. Overall response rate is about 20% in heavily pretreated patients. Even patients after bone marrow transplantation showed response. This suggests to treat patients in a earlier phase of their disease. Combination of interferon with radiotherapy or chemotherapy might be promising. Prospective studies investigate the value of IFN for maintenance. It seems that patients treated with IFN have less relapses and better immunorestorations. Whether IFN can prevent secondary malignancies is also topic of these investigations. As IFN has complex side effects it should be applied only in controlled studies.
authors.affiliation: III. Medizinischen Abteilung, Hanusch-Krankenhauses, Wien.
authors.forename: R
authors.initials: R
authors.lastname: Heinz
authors.forename: M
authors.initials: M
authors.lastname: Möstl
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D010166:Palliative Care
chemical_list: D016898:Interferon-alpha